Treatment for millions at stake in 'skinny label' Supreme Court case

The Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. ruling could have a major effect on incentives to invest in research for FDA‑approved medicines.

Raccontata dawashingtonexaminer.com